New study tests if tumor genes and organoids can outsmart pancreatic cancer
NCT ID NCT06615830
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study will enroll 185 people with metastatic pancreatic cancer to see if analyzing tumor genes and lab-grown organoids can predict which standard chemotherapy regimens work best. Researchers will compare predicted drug sensitivity to actual patient outcomes. The tests are experimental and not used to guide treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Transcriptome-based OncoTreat/OncoTarget testing and patient-derived organoids
What this could lead to
If successful, this could show that combining genetic analysis with organoid testing helps predict effective treatments for pancreatic cancer, paving the way for more personalized therapy.
What could go wrong
This is an observational study, not a treatment trial. The tests are experimental and not yet proven to improve outcomes. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••